Vitamin D Treatment in Patients With Chronic Hepatitis C

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2008 by Hillel Yaffe Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT00804752
First received: December 7, 2008
Last updated: December 8, 2008
Last verified: December 2008
  Purpose

We hypothesize that patients with Ch.HCV have a low level of vitamin D, and that by raising their vitamin D levels by adding it to their standard treament of Pegylated Interferon and Ribavirin, there will be an increase in their sustained virological response.


Condition Intervention
Chronic Hepatitis C
Drug: Adding vitamin D
Drug: Vitamin D

Study Type: Interventional

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • To increase the sustained virological response [ Time Frame: One year ] [ Designated as safety issue: No ]

Arms Assigned Interventions
Experimental: Vitamin D
An addition of Vitamin D to the standard treatment
Drug: Adding vitamin D
Adding 1000IU/Vitamin D daily
Drug: Vitamin D
Addition of 1000IU/day Vitamin D

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic Hepatitis C Genotype 1

Exclusion Criteria:

  • Vitamin D intoxication Renal Failure Liver Failure Malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00804752

Locations
Israel
Hillel Yaffe Medical Center Recruiting
Hadera, Israel, 38100
Contact: Saif Abu-Mouch, MD       saif@hy.health.gov.il   
Principal Investigator: Saif Abu-Mouch, MD         
Sub-Investigator: Jacob Yarchovski, MD         
Sub-Investigator: Carlos Singer, MD         
Sub-Investigator: Abed El-Rauf Zeina, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

No publications provided

Responsible Party: Dr. Saif Abu-Mouch, Hepatology Clinic, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT00804752     History of Changes
Other Study ID Numbers: 0040-08-HYMC
Study First Received: December 7, 2008
Last Updated: December 8, 2008
Health Authority: Israel: Ministry of Health

Keywords provided by Hillel Yaffe Medical Center:
Patients with Chronic Hepatitis C

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis C
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Vitamin D
Ergocalciferols
Vitamins
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions
Micronutrients
Growth Substances

ClinicalTrials.gov processed this record on July 23, 2014